Summary
Zoetis Inc. reported strong financial performance for the second quarter and the first half of 2018, demonstrating robust revenue growth and improved profitability. Total revenue increased by 12% in the second quarter and 11% for the first half of the year, driven by solid volume increases in both in-line and new products, particularly in the companion animal segment. The company also benefited from favorable foreign exchange movements, contributing to the reported growth. Profitability saw a significant boost, with net income attributable to Zoetis Inc. rising 55% for the quarter and 52% for the half-year. This was driven by higher revenues, improved cost of sales as a percentage of revenue due to manufacturing efficiencies and favorable foreign exchange, and a substantially lower effective tax rate resulting from the Tax Cuts and Jobs Act of 2017. Key operational drivers included strong performance in the companion animal segment, particularly in dermatology products and new offerings like Simparica®, across both U.S. and international markets. The international segment showed impressive growth, with a 15% revenue increase in the quarter and 16% for the half-year, fueled by both companion and livestock product sales. The company's effective tax rate dropped significantly due to the lower U.S. federal corporate tax rate and a beneficial tax adjustment, contributing to the substantial net income growth. Zoetis continues to invest in research and development, with R&D expenses increasing by 19% for the quarter, supporting future innovation.
Financial Highlights
52 data points| Revenue | $1.42B |
| Cost of Revenue | $447.00M |
| Gross Profit | $968.00M |
| SG&A Expenses | $359.00M |
| Operating Expenses | $973.00M |
| Interest Expense | $46.00M |
| Net Income | $382.00M |
| EPS (Basic) | $0.79 |
| EPS (Diluted) | $0.79 |
| Shares Outstanding (Basic) | 483.80M |
| Shares Outstanding (Diluted) | 487.50M |
Key Highlights
- 1Strong revenue growth: Total revenue increased by 12% for the second quarter of 2018 and 11% for the first six months, driven by a 9% and 8% operational growth respectively, primarily from increased volume in key product lines.
- 2Significant net income improvement: Net income attributable to Zoetis Inc. surged by 55% in the second quarter and 52% in the first half, showcasing enhanced profitability.
- 3Lower effective tax rate: The effective tax rate decreased significantly from 28.4% in Q2 2017 to 12.6% in Q2 2018, and from 28.7% to 14.3% for the six-month period, largely due to the Tax Cuts and Jobs Act of 2017.
- 4Companion Animal segment strength: The companion animal business continues to be a key growth driver, with revenue up 15% in the U.S. and 24% internationally for the quarter, bolstered by dermatology products and new offerings.
- 5International market expansion: The International segment delivered robust performance with revenue up 15% in the quarter and 16% year-to-date, demonstrating successful global market penetration.
- 6Increased R&D investment: Research and development expenses rose by 19% in the quarter and 13% year-to-date, reflecting Zoetis' commitment to innovation and future product development.
- 7Improved Cost of Sales Efficiency: Cost of sales as a percentage of revenue decreased significantly, indicating improved manufacturing efficiencies and favorable foreign exchange impacts.